On Friday, Revance Therapeutics Inc (NASDAQ: RVNC) was -6.98% down from the session before settling in for the closing price of $4.44. A 52-week range for RVNC has been $4.21 – $37.98.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales surged by 815.27% over the last five years. When this article was written, the company’s average yearly earnings per share was at 23.04%. With a float of $95.22 million, this company’s outstanding shares have now reached $104.22 million.
The firm has a total of 597 workers. Let’s measure their productivity.
Revance Therapeutics Inc (RVNC) Breakdown of a Key Holders of the stock
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Revance Therapeutics Inc stocks. The insider ownership of Revance Therapeutics Inc is 8.64%, while institutional ownership is 75.45%. The most recent insider transaction that took place on Mar 18 ’24, was worth 47,204. In this transaction CFO of this company sold 9,361 shares at a rate of $5.04, taking the stock ownership to the 192,666 shares. Before that another transaction happened on Mar 18 ’24, when Company’s President sold 9,211 for $5.04, making the entire transaction worth $46,446. This insider now owns 167,550 shares in total.
Revance Therapeutics Inc (RVNC) Recent Fiscal highlights
Wall Street market experts anticipate that the next fiscal year will bring earnings of 25.31 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 23.04% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 11.60% during the next five years compared to 0.57% growth over the previous five years of trading.
Revance Therapeutics Inc (NASDAQ: RVNC) Trading Performance Indicators
You can see what Revance Therapeutics Inc (RVNC) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 3.29. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 1.84.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -3.79, a number that is poised to hit -0.48 in the next quarter and is forecasted to reach -0.66 in one year’s time.
Technical Analysis of Revance Therapeutics Inc (RVNC)
Analysing the last 5-days average volume posted by the [Revance Therapeutics Inc, RVNC], we can find that recorded value of 1.53 million was lower than the volume posted last year of 1.78 million. As of the previous 9 days, the stock’s Stochastic %D was 15.65%. Additionally, its Average True Range was 0.36.
During the past 100 days, Revance Therapeutics Inc’s (RVNC) raw stochastic average was set at 0.53%, which indicates a significant decrease from 3.23% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 58.92% in the past 14 days, which was lower than the 89.91% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $5.36, while its 200-day Moving Average is $11.04. Now, the first resistance to watch is $4.35. This is followed by the second major resistance level at $4.58. The third major resistance level sits at $4.70. If the price goes on to break the first support level at $4.00, it is likely to go to the next support level at $3.88. Now, if the price goes above the second support level, the third support stands at $3.65.
Revance Therapeutics Inc (NASDAQ: RVNC) Key Stats
There are 104,216K outstanding shares of the company, which has a market capitalization of 430.43 million. As of now, sales total 234,040 K while income totals -323,990 K. Its latest quarter income was 69,800 K while its last quarter net income were -55,700 K.
